66 results on '"Miglioresi, L"'
Search Results
2. AF.69 AN UNEXPECTED DIAGNOSIS FOR A RECTAL BUMP
3. A snapshot of urgent upper gastrointestinal endoscopy care during the COVID‐19 outbreak in Italy
4. How to Improve Compliance With Dermatologic Screening in Liver Transplant Recipients: Experience in a (Spoke) Peripheral Center for Follow-up
5. P.03.27 GIANT GASTRIC TRICHOBEZOAR: A CASE ULTRASONOGRAPHICALLY SUSPECTED, ENDOSCOPICALLY CONFIRMED AND LAPAROSCOPICALLY MANAGED
6. Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
7. Eradication of Hepatitis C After Liver Transplantion: Consequences for the Organization of the Transplant Patient's Follow-up
8. Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment
9. P.01.2 HBV INFECTION PREVALENCE AND VACCINATION IN AN IMMIGRANT POPULATION IN ROME
10. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group
11. Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound
12. P0367 : Sarcopenia is associated with a reduced survival in patients with hepatocarcinoma undergoing sorafenib treatment
13. Sarcopenia at First Diagnosis Predicts a Reduced Survival in Patients Affected by Hepatocarcinoma
14. SARCOPENIA IS ASSOCIATED WITH A REDUCED SURVIVAL IN PATIENTS WITH HEPATOCARCINOMA UNDERGOING SORAFENIB TREATMENT
15. P885 RECIPIENT AND DONOR GENDER MATCH PREDICTS THE OUTCOME OF ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C
16. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study
17. P.17.12 SCREENING FOR HCV INFECTION IN A COHORT OF IMMIGRANTS WITH A RAPID ORAL FLUID TEST
18. The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post-liver transplant (LT) HCV recurrence
19. Long term NUC treatment in hepatitis B virus HBeAg negative genotype D patients and risk for hepatocellular carcinoma: Evidence from the CLEO cohort study
20. Recipient and donor gender match predicts the outcome of antiviral therapy for recurrent hepatitis C
21. De Novo Malignancies Following Liver Transplantation: Results From a Multicentric Study in Central and Southern Italy, 1990–2008
22. 484 IMPACT OF LIVER FIBROSIS IN DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS TREATED WITH ANTIVIRAL THERAPY: LONG TERM FOLLOW UP STUDY
23. 139 AN UNFAVORABLE INTERACTION BETWEEN DONOR AGE AND LATENT RECIPIENT CYTOMEGALOVIRUS (CMV) INFECTION AFTER LIVER TRANSPLANTATION (LT): INSIGHTS FROM THE LIVER MATCH STUDY
24. P.18.2 LONG-TERM MAINTENANCE OF SVR IN DIFFICULT-TO-TREAT HCV GENOTYPES IN LIVER TRANSPLANT RECIPIENTS WITH HCV RECURRENCE
25. T-45 Features of patients with extrahepatic metastasis of hepatocellular carcinoma and clinical impact on survival: experience of a single Italian center
26. P.04.4 SVR TO ANTIVIRAL TREATMENT FOR POST-OLT RECURRENT HCV HEPATITIS CAN BE IMPROVED BY THE USE OF GROWTH FACTORS
27. P.03.6 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
28. P.04.9 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
29. F-46 Graft survival is worse in HCV positive females transplanted with male donor grafts
30. 563 ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FORM THE AISF-RECOLT-C GROUP
31. 523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION
32. P.1.54: TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN “AISF RECOLT-C” STUDY
33. P.1.3: ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT LIVER TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
34. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
35. 561 BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
36. P.1.7: A SVR TO POST-LT ANTIVIRAL TREATMENT IMPROVES LONG-TERM SURVIVAL IN PATIENTS WITH GENOTYPE 1 HCV RECURRENCE: AN “AISF RECOLT-C” GROUP STUDY
37. P.1.2: THE PERSISTENCE OF HCV REPLICATION IS ASSOCIATED WITH AN INCREASED MORTALITY RATE IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP
38. PC.1.4: THE BEST MATCHING FOR HCV GENOTYPE 1 LIVER TRANSPLANT RECIPIENTS IS PREDICTED BY HCV1-STAR. A STUDY FROM AISF RECOLT-C DATABASE
39. 579 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
40. 427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME
41. 464 TREATMENT OF THE “UNCOMMON” HCV GENOTYPE 4 INFECTION RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN MULTICENTRIC EXPERIENCE
42. P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP
43. 532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP
44. T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group
45. OC-7 A SVR to post-LT antiviral treatment improves long-term survival in patients with genotype 1 HCV recurrence: An “AISF RECOLT-C” Group Study
46. F-39 Is the primary immunosuppressive drug playing a role on the response to antiviral treatment for post-transplant HCV recurrence?
47. T-43 Treatment of the “uncommon” HCV genotype 4 infection recurrence after liver transplantation. Data from AISF RECOLT-C group
48. T-24 Donor-related characteristics as predictors of sustained virologic response to antiviral therapy in recurrent hepatitis C after liver transplantation
49. F-48 HCV relapses occur within 3 months after treatment in liver transplanted patients receiving pegylated IFN and ribavirin
50. F-31 The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.